Zheng Lv

1.8k citations
31 papers · 1.3k indexed · 1 hit paper · h-index 13
Topics
Cancer Immunotherapy and Biomarkers (6 papers)Cancer Genomics and Diagnostics (5 papers)DNA Repair Mechanisms (3 papers)
Partner nations
ChinaUnited States

In The Last Decade

Zheng Lv

28 papers receiving 1.3k citations

Hit Papers

Predictive biomarkers for cancer immunotherapy with immun...20202026202220242020100200300

Peers

Zheng Lv
Comparison fields: 5 of 92
  • Molecular Biology 637
  • Oncology 538
  • Cancer Research 497
  • Immunology 307
  • Pulmonary and Respiratory Medicine 212
Replace Chenfei Zhou with:
Chenfei Zhou China
Jan Dominik Kuhlmann Germany
Tobias Anzeneder Germany
Gengtai Ye China
Meisi Yan China
Yacine Barèche Belgium
Htoo Zarni Oo Canada
Véronique Secq France
Jennifer L. Santos Canada
Zehang Jiang China
Zheng Lv relative to Chenfei Zhou China Chenfei Zhou's profile →
Citations per field
00.5×1.5×
Chenfei Zhou · 1×
Citations per year

Countries citing papers authored by Zheng Lv

Since Specialization
Citations

This map shows the geographic impact of Zheng Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zheng Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zheng Lv more than expected).

Fields of papers citing papers by Zheng Lv

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zheng Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zheng Lv. The network helps show where Zheng Lv may publish in the future.

Co-authorship network of co-authors of Zheng Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Zheng Lv. A scholar is included among the top collaborators of Zheng Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zheng Lv. Zheng Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 2
3 39
4 0
5 0
6 7
7 1
8 7
9 2
10 5
11 5
12 1
13 249
14
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitorsbreakdown →
318
15 3
16 328
17 23
18 27
19 82
20 21

About Zheng Lv

Zheng Lv is a scholar working on Cancer Research, Oncology and Dermatology, having authored 31 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Cancer Genomics and Diagnostics (5 papers) and DNA Repair Mechanisms (3 papers). The work is most often cited by research in Cancer Research (497 citations), Oncology (538 citations) and Immunology (307 citations). Zheng Lv has collaborated with scholars based in China and United States. Frequent co-authors include Jiuwei Cui, Rilan Bai, Dongsheng Xu, Naifei Chen, Huimin Tian, Lingyu Li, Ling Bai, Lin Jia, Wei Song and Zhonghua Du. Their work appears in journals such as Scientific Reports, Annals of Oncology and Genome biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026